S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
NASDAQ:STAB

Statera BioPharma Stock Forecast, Price & News

$3.22
+0.38 (+13.38 %)
(As of 10/15/2021 04:00 PM ET)
Add
Compare
Today's Range
$2.85
$3.85
50-Day Range N/A
52-Week Range
$2.11
$10.97
Volume2.51 million shs
Average Volume265,103 shs
Market Capitalization$82.59 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
30 days | 90 days | 365 days | Advanced Chart
Receive STAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Statera BioPharma and its competitors with MarketBeat's FREE daily newsletter.


About Statera BioPharma

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STAB
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
$260,000.00
Book Value
$0.15 per share

Profitability

Net Income
$-2.40 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$82.59 million
Next Earnings Date
11/15/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1352nd out of 1,361 stocks

Pharmaceutical Preparations Industry

665th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Statera BioPharma (NASDAQ:STAB) Frequently Asked Questions

What stocks does MarketBeat like better than Statera BioPharma?

Wall Street analysts have given Statera BioPharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Statera BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Statera BioPharma's next earnings date?

Statera BioPharma is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Statera BioPharma
.

Who are Statera BioPharma's key executives?

Statera BioPharma's management team includes the following people:
  • Michael Kevin Handley, President, Chief Executive Officer & Director
  • Taunia S. Markvicka, Chief Operating Officer & Director
  • Peter J. Aronstam, Chief Financial Officer
  • Andrei V. Gudkov, Global Head-Research & Development
  • Clifford A. Selsky, Chief Medical Officer

What is Statera BioPharma's stock symbol?

Statera BioPharma trades on the NASDAQ under the ticker symbol "STAB."

How do I buy shares of Statera BioPharma?

Shares of STAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Statera BioPharma's stock price today?

One share of STAB stock can currently be purchased for approximately $3.22.

How much money does Statera BioPharma make?

Statera BioPharma has a market capitalization of $82.59 million and generates $260,000.00 in revenue each year.

How many employees does Statera BioPharma have?

Statera BioPharma employs 4 workers across the globe.

What is Statera BioPharma's official website?

The official website for Statera BioPharma is www.staterabiopharma.com.

How can I contact Statera BioPharma?

The company can be reached via phone at (888) 613-8802.


This page was last updated on 10/17/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.